Laurus Labs Limited — Investor Meet, 29-01-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance**: Laurus Labs reported Q3 revenue of ₹1,415 crores, marking an 18% year-on-year growth, driven primarily by robust demand in the CDMO sector and steady performance in the formulation division. Gross margins remained strong at 56.9%, while EBITDA increased to ₹285 crores, yielding an EBITDA margin of 20.1%. The company reported a profit after tax of ₹92 crores for the quarter, translating to a 6.8% ROCE, reflecting ongoing investments and operational scaling.

2. **Future Outlook and Growth Drivers**: Management expressed optimism for continued revenue acceleration, especially in the CDMO business, which recorded its highest quarterly sales in eight quarters, nearing ₹400 crores. The strategic focus includes the launch of high-potency small molecule projects and major pipelines in clinical development, capitalizing on strong customer demand.

3. **Order Book and Operational Updates**: Laurus is actively managing over 90 projects, mixing human health and animal health offerings. The ARV API revenue slipped 7% to ₹531 crores due to prioritized capacity allocations, although the order book remained robust. The company anticipates growth in the API segment next year, supported by strategic initiatives and project ramp-ups.

4. **Analyst Q&A Insights (Detailed)**:

- **Revenue and Profitability**: Management provided clarity on revenue drivers and affirmed that the ARV business remains a critical cash generator, expected to stabilize between ₹2,300 and ₹2,500 crores annually.

- **Market Position and Competitive Landscape**: The company is adapting its operational focus towards higher-margin, complex APIs and has strengthened its market position with the recent investment from Eight Roads for fermentation capacity expansion.

- **Operational Challenges or Risks**: Questions regarding regulatory impacts and supply chain diversification were addressed, emphasizing that they have not experienced significant challenges or deterioration in RFP flow.

- **Capex and Capital Allocation**: Continued investments are aimed at enhancing high-value business segments, with a clear strategy to gradually deleverage as operational performance improves.

- **Strategic Priorities and Long-Term Vision**: The focus remains on innovation and capacity expansion within the CDMO space, with expectations of substantial growth in FY26.

5. **Market or Regulatory Updates**: There were no significant regulatory updates impacting the operational landscape, but management acknowledged ongoing shifts in global procurement dynamics, specifically in the ARV sector.

6. **Strategic Focus Areas**: Laurus continues to prioritize innovation, enhancing operational efficiencies, and expanding market reach, alongside managing investments in high-growth segments.

7. **Investor Insight**: The financial health of Laurus Labs, paired with a robust growth trajectory and strategic expansions, supports a 'buy' position based on the sustained demand in CDMO and a healthy order book, albeit with awareness of potential volatility in future supply chain dynamics and regulatory environments.